MECAMYLAMINE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MECAMYLAMINE HYDROCHLORIDE (MECAMYLAMINE HYDROCHLORIDE).
Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (nAChRs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.
| Metabolism | Primarily hepatic with some renal excretion. Metabolized by cytochrome P450 enzymes, likely multiple isoforms, though specific enzymes not fully characterized. |
| Excretion | Renal: 50-70% unchanged; biliary/fecal: minimal (less than 5%) |
| Half-life | Terminal elimination half-life is approximately 12-24 hours; clinically, this allows once or twice daily dosing but requires dose adjustment in renal impairment. |
| Protein binding | Approximately 0-20% bound, primarily to albumin and alpha-1 acid glycoprotein; low binding is clinically insignificant. |
| Volume of Distribution | Vd approximately 1-2 L/kg; extensive tissue distribution indicates high penetration into tissues. |
| Bioavailability | Oral: approximately 20-50% due to incomplete absorption and first-pass metabolism. |
| Onset of Action | Oral: 30-120 minutes; hypotensive effect may be seen within 1-2 hours. |
| Duration of Action | Oral: 6-12 hours; clinical antihypertensive effect lasts about 6-8 hours, allowing twice-daily dosing. |
Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in patients with renal insufficiency (eGFR <30 mL/min). For mild to moderate impairment, reduce dose by 50% and monitor closely. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), reduce dose by 50% and titrate slowly. |
| Pediatric use | Not recommended for use in children due to lack of safety and efficacy data. |
| Geriatric use | Initiate at 2.5 mg once daily; increase slowly with careful monitoring due to increased sensitivity to hypotensive effects and higher risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MECAMYLAMINE HYDROCHLORIDE (MECAMYLAMINE HYDROCHLORIDE).
| Breastfeeding | Excreted in breast milk; M/P ratio not established. Risk of infant ganglionic blockade (hypotension, constipation, urinary retention). Contraindicated in breastfeeding due to potential for serious adverse effects. |
| Teratogenic Risk | FDA Pregnancy Category C. Animal reproduction studies have not been conducted; potential fetal harm unknown. Mecamylamine crosses placenta. First trimester: theoretical risk of teratogenicity due to ganglionic blockade; avoid unless essential. Second/third trimester: may cause fetal hypotension, hypoxia, meconium aspiration, and neonatal respiratory depression due to maternal hypotension and reduced uterine blood flow. Neonatal withdrawal syndrome reported with chronic use. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to mecamylamine or any component.","Coronary artery disease (risk of precipitation of angina).","Recent myocardial infarction.","Glaucoma (may increase intraocular pressure).","Uremia.","Concurrent use with ganglionic blocking agents."]
| Precautions | ["May cause orthostatic hypotension, syncope, and impaired mental alertness.","Caution in patients with poor renal function, prostatic hypertrophy, or pyloric stenosis.","Risk of rebound hypertension upon abrupt discontinuation.","Mecamylamine may precipitate urinary retention in patients with bladder dysfunction."] |
Loading safety data…
| Fetal Monitoring | Maternal: blood pressure (avoid hypotension, target >100/60 mmHg), heart rate, signs of cholinergic blockade (blurred vision, constipation, urinary retention). Fetal: heart rate monitoring, growth scans (risk of intrauterine growth restriction with prolonged maternal hypotension). Neonatal: observe for respiratory depression, weak cry, poor feeding in first 24-48 hours. |
| Fertility Effects | No human data on fertility impairment. In animals, reduced fertility at high doses due to anticholinergic effects. Potential reversible impairment of spermatogenesis or ovulation due to autonomic blockade. |